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ABSTRACT
Purpose: To determine the effectiveness of adjuvant dendritic cell (DC) vaccination to induce tumor-
speciﬁc immunological responses in stage III melanoma patients.
Experimental design: Retrospective analysis of stage III melanoma patients, vaccinated with autologous
monocyte-derived DC loaded with tumor-associated antigens (TAA) gp100 and tyrosinase after radical
lymph node dissection. Skin-test inﬁltrating lymphocytes (SKILs) obtained from delayed-type
hypersensitivity skin-test biopsies were analyzed for the presence of TAA-speciﬁc CD8C T cells by
tetrameric MHC-peptide complexes and by functional TAA-speciﬁc T cell assays, deﬁned by peptide-
recognition (T2 cells) and/or tumor-recognition (BLM and/or MEL624) with speciﬁc production of Th1
cytokines and no Th2 cytokines.
Results: Ninety-seven patients were analyzed: 21 with stage IIIA, 34 with stage IIIB, and 42 had stage IIIC
disease. Tetramer-positive CD8C T cells were present in 68 patients (70%), and 24 of them showed a
response against all 3 epitopes tested (gp100:154–162, gp100:280–288, and tyrosinase:369–377) at any
point during vaccinations. A functional T cell response was found in 62 patients (64%). Rates of peptide-
recognition of gp100:154–162, gp100:280–288, and tyrosinase:369–377 were 40%, 29%, and 45%,
respectively. Median recurrence-free survival and distant metastasis-free survival of the whole study
population were 23.0 mo and 36.8 mo, respectively.
Conclusions: DC vaccination induces a functional TAA-speciﬁc T cell response in the majority of stage III
melanoma patients, indicating it is more effective in stage III than in stage IV melanoma patients.
Furthermore, performing multiple cycles of vaccinations enhances the chance of a broader immune
response.
Abbreviations: CI, conﬁdence interval; DC, dendritic cell(s); DMFS, distant metastasis-free survival; DTH, delayed-
type hypersensitivity; ELISPOT, enzyme-linked immunosorbent spot; FDA, Food and Drug Administration; HR, haz-
ard ratio(s); HS, human serum; IL, interleukin; KLH, keyhole limpet hemocyanin; MHC, major histocompatibility com-
plex; OS, overall survival; PBMC, peripheral blood mononuclear cells; PD-1, programmed death 1; PGE2,
prostaglandin E2; RFS, recurrence-free survival; SKIL(s), skin-test inﬁltrating lymphocyte(s); TAA, tumor-associated
antigen(s); Th, T-helper; TNF-a, tumor necrosis factor-a.
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Introduction
The incidence of stage III melanoma is rising and these patients
are at high risk of relapse, even after a radical lymph node
dissection with curative intention.1,2 Balch and colleagues
showed that 5-y survival within substages of stage III were
78%, 59%, and 40% for patients with stage IIIA, IIIB, and IIIC
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melanoma, respectively.3 There is a great medical need for
adjuvant treatments that will improve survival rates in this
population.3,4 Until recently, interferon-a was the only
approved adjuvant treatment, however it minimally improves
overall survival (OS) and is not recommended in most Euro-
pean countries because of its side effect proﬁle.5 For this rea-
son, other adjuvant therapies are currently under
investigation, among them ipilimumab,6 programmed death 1
(PD-1) inhibitors (NCT02388906, NCT02362594), and vacci-
nation strategies (NCT00796445). Adjuvant ipilimumab
10 mg/kg showed a signiﬁcant improvement of recurrence-free
survival (RFS) compared to placebo, and it has been recently
approved by the Food and Drug Administration (FDA). How-
ever, OS data have not yet been reported and treatment was
accompanied by signiﬁcant grade 3 and 4 toxicity.6
Dendritic cells (DC) are the most efﬁcient antigen-present-
ing cells of the immune system due to their capacity to activate
and prime naive T cells.7 They are essential in the induction of
antitumor immunity, and may therefore play a vital role in
anticancer immunotherapy.8,9 DC can be generated ex vivo,
activated, and loaded with tumor antigens, and then injected
into patients.7,10 We and others have treated stage IV mela-
noma patients with DC-based vaccines, and noted induction of
tumor-speciﬁc immune responses, but long-lasting clinical
responses are, thus far, limited.7,9,11,12 Since high tumor load
causes immune suppression by secretion of immunosuppres-
sive cytokines, and attraction of regulatory T cells and myeloid-
derived suppressor cells in the tumor microenvironment, DC
vaccination may be more effective as an adjuvant treatment in
stage III patients.13,14
Because the immunotherapeutic options for melanoma are
growing rapidly, immunomonitoring of patients is of great
importance in these clinical trials. For instance, enzyme-
linked immunosorbent spot (ELISPOT) assays and ﬂow cyto-
metric assays to detect antigen-speciﬁc T cells in peripheral
blood samples, are commonly used in cancer immunotherapy
trials. However, since tumor-associated antigen (TAA)-spe-
ciﬁc T cells are detected in only a minority of the peripheral
blood samples, and to date no correlation has been found
between immunological data in peripheral blood and clinical
outcome, these peripheral blood assays might not be optimal
for immunomonitoring.15
We previously described a bioassay evaluating skin-test inﬁl-
trating lymphocyte (SKIL) cultures from delayed-type hyper-
sensitivity (DTH) skin-test biopsies after DC vaccination in
stage IV melanoma patients.16 The mechanism of action of this
bioassay is based on the fact that tumor-speciﬁc T cells should
be able to invade peripheral tissues, recognize tumor antigens,
proliferate, and deliver a functional response upon tumor-spe-
ciﬁc stimulation. Antigen-speciﬁc T cells which are also able to
migrate to peripheral tissues are selected when a DTH with
TAA-loaded DC is used. After short-time culturing of these
SKILs from DTH skin biopsies, they are challenged by target
cells loaded with deﬁned tumor peptides and target cells that
express naturally processed tumor antigens.10,16
The aim of this retrospective study was to explore the
effectiveness of adjuvant DC vaccination to induce tumor-
speciﬁc immunological responses in stage III melanoma
patients.
Results
Patient and vaccine characteristics
The aim of this study was to evaluate immunological
responses to DC vaccination. Since the DTH skin-test biop-
sies were taken after each cycle of three vaccinations,
patients should have had completed at least one cycle to be
immunologically evaluable. In total, 97 out of 99 (98%)
HLA02:01-positive stage III melanoma patients met this
criterion. Baseline characteristics of the evaluable patients
are listed in Table 1. Overall, 21 patients (22%) had stage
IIIA, 34 (35%) had stage IIIB, and 42 (43%) had stage IIIC
disease. The phenotype of the generated DC (expression of
major histocompatibility complex (MHC) class I/II and co-
stimulatory molecules) was determined by ﬂow cytometry
and the produced vaccines met the quality release criteria
(Fig. S1A).11 Flow cytometry showed intracellular expres-
sion of both TAA (gp100 and tyrosinase) in DC electropo-
rated with mRNA (Fig. S1B).
The median follow-up time from apheresis to patient death
or censoring was 47.4 mo (range 3.7–168.6 mo).
Table 1. Baseline characteristics.
Dendritic cell vaccinated stage
III melanoma patients N D 97(%)
Sex
Male 60 (62)
Female 37 (38)
Age, years
Mean (range) 50.6 (22–79)
Age in categories, years
21–30 4 (4)
31–40 19 (20)
41–50 23 (24)
51–60 31 (32)
61 20 (21)
Breslow thickness primary melanoma, mm
1.0 7 (7)
1.01–2.0 26 (27)
2.01–4.0 25 (26)
>4.0 31 (32)
No primary/unknown 8 (8)
Ulceration of primary melanoma
Absent 68 (70)
Present 29 (30)
Histological type melanoma
Superﬁcial spreading 54 (56)
Nodular 22 (23)
Acral lentiginous 1 (1)
Lentigo maligna 1 (1)
Spitzoid 2 (2)
No primary/unknown 17 (18)
N stage at inclusion
N1a 24 (25)
N1b 24 (25)
N2a 5 (5)
N2b 14 (14)
N3 30 (31)
AJCC pathological stage
IIIA 21 (22)
IIIB 34 (35)
IIIC 42 (43)
Adjuvant radiotherapya
No 91 (94)
Yes 6 (6)
aAdjuvant radiotherapy was given after the apheresis, but before the ﬁrst
vaccination.
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Immunological responses to KLH
Immunological responses to keyhole limpet hemocyanin (KLH)
were used as a surrogate marker for immune competence. After
vaccination, patients were assessed for the presence of KLH-spe-
ciﬁc T cells in their peripheral blood mononuclear cells (PBMC)
and for antibody responses against KLH in their serum. After
the ﬁrst round of vaccinations, an increased T cell proliferation
upon stimulation with KLH was found in 68 out of 80 patients
(85%) tested (Fig. S2) and anti-KLH antibodies (IgG, IgA, and/
or IgM) were detected in 62 out of 80 patients (78%) tested.
Only four patients (4%) showed no increased KLH-speciﬁc T
cell- or anti-KLH antibody-response. This was not associated
with the incapacity to develop a TAA-speciﬁc CD8C T cell
response, since two of these patients had TAA-speciﬁc T cells in
DTH skin-test biopsies. The above described results show that
the majority of this patient population is well capable of induc-
ing an immune response against the control antigen KLH.
Presence of TAA-speciﬁc CD8C T cells
DTH skin-test biopsies were taken within 2 weeks after each
cycle of vaccinations in all patients, and after short-time culture
they were analyzed for the presence of TAA-speciﬁc CD8C T
cells by tetrameric MHC-peptide complexes (Fig. 1). The pres-
ence of TAA-speciﬁc CD8C T cells recognizing any epitope
(gp100:154–162, gp100:280–288, or tyrosinase:369–377) in
SKIL cultures was shown in 68 patients (70%). A total of 24
patients (25%) had TAA-speciﬁc CD8C T cells against all three
epitopes, 27 patients (28%) showed tetramer-positive CD8C T
cells recognizing two epitopes, and there were 17 patients
(17%) with T cells against only one epitope. Fifty-two patients
(54%) had T cells against the epitope gp100:154–162, 51
patients (53%) T cells against gp100:280–288, and 40 patients
(41%) against tyrosinase:369–377. In the majority of patients
(72%), tetramer-positive T cells against any epitope were
observed after the ﬁrst cycle of vaccinations. Furthermore, 16
patients (24%) expanded their tetramer-positive T cell response
after cycles 2 and 3. However, a notable portion of 72 patients
with data available of consecutive rounds, lacked tetramer-posi-
tive T cells against an epitope after a positive result in a previ-
ous cycle; 29% for gp100:154–162, 35% for gp100:280–288, and
18% for tyrosinase:369–377 (Fig. 2A).
Furthermore, the DTH skin-test biopsies were analyzed for
the occurrence of a functional TAA-speciﬁc T cell response
(Fig. 1), by measuring speciﬁc production of Th1/Th2
Figure 1. Tumor antigen-speciﬁc CD8C (T)cell responses in SKIL cultures. An example is shown of a tetramer analysis of SKILs from patient II-D-12 (A). Cells were stained
with tetramers encompassing the peptides gp100:154, gp100:280, tyrosinase or an irrelevant peptide (control) and with anti-CD8C mAb. This analysis showes presence of
TAA-speciﬁc CD8C T cells against both gp100 epitopes and tyrosinase. Furthermore, a cytokine proﬁle of the same T cells is shown after stimulation with T2 cells loaded
with gp100 or tyrosinase peptide, BLM cells transfected with gp100 or tyrosinase, or MEL624 cells expressing both gp100 and tyrosinase (B). Functional TAA-speciﬁc T cells
against gp100 and tyrosinase are present with a clear production of IFNg and/or IL-2, but without IL-5 production.
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Figure 2. SKILs analysis in time. Skin-test inﬁltrating lymphocytes from DTH skin-test biopsies were analyzed for the presence of tetramer-positive CD8C T cells (A) and a
functional T cell response against individual epitopes (B). Three epitopes were tested, gp100:154, gp100:280, and tyrosinase. Unﬁlled/ﬁlled circles represent negative/pos-
itive tests. The black, red, and blue circles match to the ﬁrst, second, and third cycle of vaccinations, respectively. Tumor-speciﬁc T cells are already seen after the ﬁrst cycle
in a large amount of patients. T cells against other epitopes were detected in a proportion of patients after cycle 2 and 3. However, in some patients T cells against an epi-
tope were not detected after a positive result in the previous cycle. This is more often seen for tetramer-positive T cells than for a functional T cell response. The distant
metastasis-free survival (DMFS) of each individual patient is shown with a cut-off at 5 y. Arrows indicate an ongoing DMFS.
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cytokines in response to T2 cells pulsed with gp100:154–162,
gp100:280–288, or tyrosinase:369–377 (peptide-recognition),
BLM transfected with gp100/tyrosinase and Mel624 (tumor-
recognition). A functional TAA-speciﬁc T cell response (pep-
tide-recognition and/or tumor-recognition) was found in
62 patients (64%), of whom 60 patients (97%) showed tetra-
mer-positive T cells. Rates of peptide-recognition of
gp100:154–162, gp100:280–288, and tyrosinase:369–377 were
40%, 29%, and 45%, respectively. Tumor-recognition was
found in 47 patients (49%), of whom 25 patients showed a
functional response against Mel624. As with the test using tet-
rameric MHC-peptide complexes, in some patients the func-
tional assay for peptide-recognition showed no functional T
cells after a positive result in a previous cycle; 6% for
gp100:154–162, 8% for gp100:280–288, and 6% for tyrosi-
nase:369–377 (Fig. 2B).
Besides the DTH skin-test biopsies, peripheral blood sam-
ples were analyzed for the occurrence of TAA-speciﬁc CD8C
T cells by tetrameric MHC-peptide complexes, and they were
found in only 15 patients (15%) at any point during vaccina-
tions. All these patients also showed tetramer-positive CD8C
T cells in the DTH skin-test biopsies.
Survival
Median RFS and distant metastasis-free survival (DMFS) of the
whole study population were 23.0 mo (95% conﬁdence interval
(CI), 9.6–36.4 mo) and 36.8 mo (95% CI, 21.0–52.7 mo),
respectively. Signiﬁcant differences in DMFS were found
between the absence or presence of ulceration and between the
different AJCC pathological stages (Table S1). A trend toward
an improved DMFS was seen in patients with tetramer-positive
T cells at any point during vaccinations, compared to patients
without tetramer-positive T cells; median DMFS 44.2 mo (95%
CI, 2.2–18.0 mo) versus 10.1 mo (95% CI, 25.9–62.5 mo; p D
0.056). The same trend was found for a functional T cell
response at any point during vaccinations; median DMFS
44.2 mo (95% CI, 26.5–61.9 mo) versus 14.0 mo (95% CI, 7.7–
20.3 mo; p D 0.066). However, for tetramer-positive T cells, as
well as for a functional T cell response, this trend was no longer
present when a conditional landmark analysis was performed
after each cycle of vaccinations in order to correct for potential
guarantee-time bias, in which only patients were analyzed who
completed that cycle (Fig. 3).
Fifty-eight patients (60%) developed distant metastases, of
whom 33 patients (57%) received some form of systemic treat-
ment. Chemotherapy (DTIC) was given to 22 patients (67%),
while 10 patients (17%) received ipilimumab and 5 patients
(8%) targeted agents, because a considerable part of these
patients was treated at a time when immune checkpoint inhibi-
tors and targeted therapies were not yet available. At the time
of data cut-off 48 deaths had occurred, and the median OS of
the whole study population was 77.7 mo (95% CI, 48.1–107.3).
Discussion
Immunomonitoring is an important part of evaluating the
effectiveness of immunotherapy. Besides peripheral blood sam-
ples, SKILs cultured from vaccine-challenged biopsies were
used to detect TAA-speciﬁc T cells. The results of the here pre-
sented study show that a TAA-speciﬁc T cell response can be
induced in the majority of stage III melanoma patients treated
Figure 3. Analyses of distant metastasis-free survival. A graphical representation of the hazard ratios (HR) of distant metastasis-free survival (DMFS) comparing patients
with or without tetramer-positive and a functional T cell response in DTH skin-test biopsies, using Cox proportional-hazard models. HR less than 1 deﬁnes a better DMFS
for patients with tumor-speciﬁc T cells. Horizontal lines represent 95% conﬁdence intervals. A trend for a lower risk of distant metastases is seen for patients with tetra-
mer-positive T cells and a functional T cell response at any point during the vaccinations as compared with patients without a T cell response. However, conditional land-
mark analyses after cycle 1 (n D 97), cycle 2 (n D 72), and cycle 3 (n D 56) show no difference in risk of distant metastases between patients with or without tetramer-
positive T cells and a functional T cell response.
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with adjuvant DC vaccination following a radical lymph node
dissection.
Using SKIL cultures could have some advantages compared
to commonly used tetramer analysis or ELISPOT assays of
TAA-speciﬁc T cells in peripheral blood. First of all, SKIL cul-
tures select TAA-speciﬁc T cells which are able to extravasate
and migrate into peripheral tissues, while it is unknown if
TAA-speciﬁc T cells in peripheral blood have these capabilities.
Furthermore, peripheral blood samples show a lower preva-
lence of TAA-speciﬁc T cells, probably because most T cells are
gathered in the lymphoid organs. Therefore, SKILs from DTH
skin-test biopsies may be more suitable for immunomonitoring
than PBMC in DC vaccinated patients, despite the fact that
these biopsies are more time-consuming.
SKILs were evaluated according to the presence of TAA-
speciﬁc CD8C T cells by tetrameric MHC-peptide complexes.
Tetramer-positive T cells recognizing one or more epitopes
were found in 70% of patients, of whom a vast majority
already showed T cells against an epitope after the ﬁrst cycle
of vaccinations. Furthermore, the chance of a broader
immune response is enhanced by performing multiple cycles
of vaccinations, because T cells against other epitopes were
detected for the ﬁrst time after the following cycles in many
patients with tetramer-positive T cells during a previous
cycle. Tumor-speciﬁc T cell responses might be more exten-
sive than only against the three HLA-A02:01-binding epito-
pes tested, especially in patients vaccinated with DC
electroporated with mRNA, since these DC present more
epitopes. Furthermore, because of epitope spreading the
tumor-speciﬁc immune response might also be more wide-
spread in patients vaccinated with peptide-pulsed DC.17
Besides using tetrameric MHC-peptide complexes, this SKIL
analysis integrates the measurement of cytokine proﬁles, and
therefore it is possible to differentiate between T-helper (Th)
1 and Th2 immune responses. Th1-type cytokines are impor-
tant in pro-inﬂammatory cellular responses, which are desir-
able for antitumor immunity, while Th2-type cytokines are
more involved in anti-inﬂammatory responses.18 A func-
tional T cell response, deﬁned as speciﬁc production of Th1
cytokines and no Th2 cytokines in response to antigen-
expressing target cells, was found in 64% of patients, which
is clearly more frequent compared to patients with distant
metastases receiving DC vaccinations (23%).19 A total of
40% of stage III patients already had a functional T cell
response after the ﬁrst cycle of vaccinations, indicating that
the observed difference is not solely explained by more cycles
of vaccinations. In addition, considerable more stage III than
stage IV patients showed a broader immune response; tetra-
mer-positive CD8C T cells recognizing multiple epitopes
were found in 52% and 14% of patients, respectively.19 Of
course, false-positivity must always be considered in diagnos-
tic tests, but the chance of false-positive results is assumed to
be low since the different assays include negative controls as
comparison. The occurrence of an adequate T cell response
is negatively inﬂuenced by many factors, like immunosup-
pressive cytokines, immune checkpoints, regulatory T cells,
and myeloid-derived suppressor cells. These factors are more
frequently observed in patients with a higher tumor burden,
and interact at different levels of the cancer immunity cycle,
e.g., priming, activation, and proliferation of T cells, and
inﬁltration of T cells in the tumor.14,20 In conclusion, DC
vaccination is more effective in producing a tumor-speciﬁc T
cell response in stage III than in stage IV melanoma patients.
Part of the patients with tetramer-positive T cells or a func-
tional T cell response against a tumor-speciﬁc peptide did not
show these T cells in the DTH skin test after a subsequent cycle
of vaccinations. First, this might be caused by a low sensitivity of
the test with false-negative results. Second, it might indicate that
there is a lack of induction of memory in these patients. A ﬁnal
reason that TAA-speciﬁc T cells are no longer detected might be
the absence of in vivo stimulation of these T cells by tumor cells,
which might have been killed during the previous cycle.
A trend toward a better DMFS was found in patients with a
tumor-speciﬁc T cell response at any point during vaccinations,
when compared to patients without TAA-speciﬁc response.
However, this difference might be explained by guarantee-time
bias, since DMFS is compared across groups deﬁned by an
event occurring sometime during follow-up.21 Therefore, a
conditional landmark analysis was performed after each cycle
of vaccinations to correct for this type of bias, and this showed
no difference in DMFS between the two groups. Therefore, it
cannot be concluded that a tumor-speciﬁc T cell response in
DTH skin-test biopsies can be used as a predictive marker for
clinical outcome, despite the recognized disadvantages of a con-
ditional landmark analysis, like the omission of events occur-
ring earlier to the landmark.22
We already showed a favorable OS in stage III melanoma
patients treated with adjuvant DC vaccination, compared to
matched controls.23 Of course, no hard conclusions can be
drawn from the retrospective data we present here, but in com-
parison to the EORTC phase 3 trial with adjuvant ipilimumab
(10 mg/kg), both studies show comparable 3-y RFS rates (43%
in our cohort versus 46.5% in the ipilimumab group), which is
at least promising.6 A disadvantage of adjuvant ipilimumab is
the toxicity proﬁle, with grade 3 and 4 adverse events occurring
in 54% of patients and 52% who stopped the treatment due to
side-effects.6 This is in strong contrast to DC vaccination,
where grade 3 and 4 toxicity is rarely observed.9 There is a risk
of selection bias in the present study, since only patients were
included in whom at least one DTH was performed. However,
in only 2 out of 99 patients, DTH skin biopsies were not taken
because of early relapse of disease after vaccinations were
started. A prospective randomized clinical trial is necessary to
determine the exact position of adjuvant DC vaccination in
stage III melanoma patients.
The clinical effectiveness of DC vaccination might be
improved by increasing the number of antigens. The mela-
noma differentiation antigens gp100 and tyrosinase were
selected because they are commonly expressed on mela-
noma cells and have shown to be capable of inducing
functional cytotoxic T cells.12,24,25 However, recent ﬁndings
show that tumor-speciﬁc mutations, leading to neoanti-
gens, may drive potent antitumor responses.26 Carreno
and colleagues found that a DC vaccine with carefully
selected patient-speciﬁc neoantigens, led to an increase in
the breadth and diversity of melanoma neoantigen-speciﬁc
T cells in peripheral blood samples of three stage IV mela-
noma patients.27 As most mutated proteins are essentially
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unique to a tumor, personalized antigen selection might be
beneﬁcial in vaccination strategies.26,27 A great challenge
will be the identiﬁcation of the right immunogenic neoan-
tigens, especially in stage III melanoma patients, since
only a minimal amount of tumor material might be avail-
able.28 For this reason, and in light of tumor heterogeneity,
it might be preferable to combine commonly expressed
melanoma differentiation antigens with patient-speciﬁc
neoantigens in future DC vaccines.
In summary, DC vaccination is more effective in inducing
functional TAA-speciﬁc CD8C T cells in stage III than stage IV
melanoma patients, and performing multiple cycles of vaccina-
tions enhances the chance of a broader immune response.
A prospective randomized clinical trial must determine the
exact position of adjuvant DC vaccination in stage III mela-
noma patients.
Materials and methods
Patient characteristics
We retrospectively analyzed a cohort of 99 stage III melanoma
patients, who were enrolled in our DC vaccination studies
between December 1999 and July 2014. Patients received adju-
vant DC vaccination within 2 mo after radical lymph node dis-
section. Inclusion criteria included melanoma with
histologically proven regional metastatic disease without evi-
dence of distant metastases; World Health organization
(WHO) performance status of 0 or 1; HLA-A02:01 phenotype;
and histological proven melanoma expressing the melanoma-
associated antigens gp100 (compulsory) and tyrosinase (non-
compulsory). Patients with a second malignancy in the previ-
ous 5 y or serious concomitant disease were excluded. At least
one DTH must have been performed to be included in this
analysis, since the goal was to evaluate tumor-speciﬁc immuno-
logical responses. All studies were approved by the appropriate
Medical Ethical Review Board and written informed consent
was obtained from all patients.
Treatment schedule
All patients were vaccinated with autologous monocyte-derived
DC loaded with TAA of gp100 and tyrosinase according to a
schedule of three biweekly vaccinations, followed by a DTH
skin test within 2 weeks after each vaccination cycle. Some
patients received an extra vaccination before radical lymph
node dissection for additional imaging studies. Patients
received three cycles of vaccinations and a DTH skin-test at
approximately 6-mo intervals when no signs of distant metasta-
ses were present. Differences in protocols included the route of
administration, method of antigen loading, and combination
treatment with interleukin (IL)-2 or cisplatin (Table 2). For the
exact details of the vaccination protocols, we refer to these indi-
vidual studies.12,29-32
Vaccine preparation
Monocytes were enriched from leukapheresis products by plas-
tic adherence of blood mononuclear cells or by counterﬂow
centrifugation using Elutra-cell separator (Gambro BCT,
Lakewood, CO) and single-use, functionally sealed disposable
Elutra sets, as described before.33 Monocytes were cultured in
the presence of IL-4 (500 U/mL), GM-CSF (800 U/mL) (both
Cellgenix, Freiburg, Germany), and KLH (10 mg/mL, Calbio-
chem, Darmstadt, Germany) or Immucothel KLH (10 mg/mL,
Biosyn, Carlsbad, CA). Most protocols used DC matured with
autologous monocyte-conditioned medium (30%, v/v) supple-
mented with prostaglandin E2 (PGE2; 10 mg/mL, Pharmacia
& Upjohn, Puurs, Belgium) and 10 ng/mL tumor necrosis fac-
tor-a (TNF-a; Cellgenix, Freiburg, Germany) for 48 h or a
cocktail of 10 ng/mL TNF-a, 5 ng/mL IL-1b, 15 ng/mL, IL-6
(all Cellgenix), and 10 mg/mL PGE2.
34,35 DC in protocols 5 and
8B were matured with a cocktail of prophylactic vaccines
including BCG vaccine SSI (4% v/v, Nederlands Vaccin Insti-
tuut, Bilthoven, the Netherlands), Typhim Vi (4% v/v, Sanoﬁ
Pasteur MSD, Brussels, Belgium), and Act-HIB (4% v/v, Aven-
tis Pasteur, Brussels, Belgium), supplemented with PGE2
Table 2. Dendritic cell vaccination protocols.
Protocol Number of patients Method of antigen loading Route of administration IL-2a Cisplatin
1 1 Peptide: class I modb i.n. no no
2A 10 Peptide: class I wtc i.d. yes no
2B 8 Peptide: class I wtc i.n. yes no
2C 10 Peptide: class I wtc i.n. no no
2D 10 Peptide: class I wtc i.d. no no
2E 10 mRNAd i.n. no no
4A 4 Peptide: class I wtc C IIe i.n. no no
4B 3 Peptide: class I wtc i.n. no no
4C C D 16 mRNAd i.n. no no
5A 5 mRNAd i.v./i.d. no no
8A C B 4 mRNAd i.n. no no
9C 9 mRNAd i.v./i.d. no yesf
9D 7 mRNAd i.v./i.d. no no
Total 97
aLow-dose IL-2 (9 MIU) was administered subcutaneously once daily for 1 week starting 3 d after each vaccination.
bClass I mod; HLA class I-restricted modiﬁed gp100-derived peptides 154–162 Q!A and 280–288 A!V and HLA class I-restricted tyrosinase-derived peptide 369–377.
cClass I wt; HLA class I-restricted wild-type gp100-derived peptides 154–162 and 280–288 and HLA class I-restricted tyrosinase-derived peptide 369–377.
dmRNA; mRNA encoding full length gp100 and tyrosinase.
eClass II; HLA class II-restricted gp100-derived peptide 44–59 and tyrosinase-derived peptide 448–462 analog.
fCisplatin (50 mg/m2) was administered intravenously before each vaccination.
Abbreviations: wt, wild type; mod, modiﬁed; i.d., intradermal; i.n., intranodal; i.v., intravenous; IL-2, Interleukin-2.
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(10 mg/mL) for 48 h (TLR-DC).36 In protocol 8A, DC were
matured via electroporation with mRNA encoding CD40L,
CD70, and constitutively active TLR4.32 DC were pulsed with
two gp100-derived peptides (gp100:154–162 and gp100:280–
288) and a tyrosinase-derived peptide (tyrosinase:369–377) or
electroporated with mRNA encoding gp100 or tyrosinase.37
Quality control of DC was performed as described before.12
Cells were re-suspended and injected intradermally, or intrano-
dally, or intradermally and intravenously. Patients received a
maximum of 30 £ 106 DC intradermally, 15 £ 106 intrano-
dally, or 10 £ 106 DC intradermally plus 20 £ 106 intrave-
nously per vaccination.
KLH-speciﬁc proliferation
PBMC were isolated from heparinized blood by Ficoll–Paque
density centrifugation, and stimulated with KLH (4 mg/2£105
PBMC) in ex vivo with 2% human serum (HS). After 3 d, cells
were incubated with 3H-thymidine for 8 h and incorporation
was measured with a b-counter. Experiments were performed
in sextuplicate, non-speciﬁc proliferation upon stimulation
with ovalbumin was used as control. Proliferative response to
KLH is given as proliferation index (proliferation with KLH/
proliferation without KLH).
KLH-speciﬁc antibody production
KLH-speciﬁc antibodies were measured in the sera of patients
before and after vaccination by ELISA (www.klhanalysis.com).
Brieﬂy, microtiter plates (96 wells) were coated overnight at
4C with KLH (25 mg/mL in PBS per well). After washing the
plates, patient serum was added in duplicate for 1 h at room
temperature. After extensive washing, patient KLH-speciﬁc
antibodies were detected with mouse anti-human IgG, IgA, or
IgM antibodies labeled with horseradish peroxidase (Invitro-
gen, Waltham, USA). 3,30 5,5-tetramethyl-benzidine (Dako,
Glostrup, Denmark) was used as a substrate and plates were
measured in a microtiter plate reader at 450 nm. For quantiﬁca-
tion an isotype-speciﬁc calibration curve for the KLH response
was included in each microtiter plate.38
Skin-test inﬁltrating lymphocyte culture
Previously we observed that, in a series of patients who under-
went pre-vaccination skin-test analysis, none of the patients
had detectable levels of TAA-speciﬁc T cells prior to vaccina-
tion. Therefore, pre-vaccination skin-tests were not performed,
and we focused on in-depth analysis on the post-vaccination
samples. Skin tests were performed within 2 weeks after each
vaccination cycle as described previously.10,16 Brieﬂy, a maxi-
mum of 10 £ 105 DC loaded with either gp100, tyrosinase or
both antigens were injected intradermally in the skin of the
back of patients at different sites, 4 cm apart from each other.
After 48 h, punch biopsies (6 mm) were taken. Half of the
biopsy was stored and half manually cut and cultured for 2–4
weeks in RPMI-1640 containing 7% HS and IL-2 (100 U/mL).
Tetramer staining of SKILs
SKIL cultures were stained with tetrameric-MHC complexes
containing the HLA-A02:01-binding epitopes gp100:154–162,
gp100:280–288, or tyrosinase:369–377 as described previ-
ously.10 Tetrameric-MHC complexes recognizing HIV were
used as correction for background binding. Tetramer positivity
was deﬁned as at least 2-fold increase in the double positive
population compared to an irrelevant control antigen (HIV).
Functionality of SKILs
The production of Th1 (IFNg and IL-2) and Th2 (IL-4 and
IL-5) cytokines by SKILs was measured in supernatants after
16 h of co-culture with different target cells, to obtain a cyto-
kine proﬁle of post-vaccination SKILs. IL-4 production was not
available for all patients. The target cells were T2 cells pulsed
with gp100:154–162, gp100:280–288, and tyrosinase:369–377;
BLM (a melanoma cell line expressing HLA-A02:01 and no
endogenous expression of gp100 and tyrosinase), transfected
with control antigen G250, gp100 or tyrosinase; and an allo-
genic HLA-A02:01-positive, gp100-positive, and tyrosinase-
positive tumor cell line (Mel624). Cytokine analysis was done
by cytometric bead array (Th1/Th2 Cytokine CBA 1; BD
Pharmingen, San Diego, CA or human Th1/Th2 FlowCytomix
multiplex kit; eBioscience, Vienna, Austria), according to the
manufacturer instructions. A positive result was deﬁned as a
2-fold increase compared to stimulation with the same cell lines
pulsed with an irrelevant peptide.
SKIL culture evaluation
SKILs were evaluated according to two criteria. At ﬁrst, the pres-
ence of TAA-speciﬁc CD8C T cells, recognizing the pre-deﬁned
epitopes, by tetrameric MHC-peptide complexes.Secondly, the
occurrence of a functional TAA-speciﬁc T cell response was
measured, deﬁned by peptide-recognition (T2 cells) and/or
tumor-recognition (BLM and/or Mel624) with speciﬁc produc-
tion of Th1 cytokines and no Th2 cytokines.
Statistical analysis
RFS, DMFS, and OS were calculated from the date of apheresis
to the date of ﬁrst recurrence, distant metastases and death,
using the Kaplan–Meier method. Additionally, a conditional
landmark analysis was performed to evaluate the effect of the
occurrence of (functional) TAA-speciﬁc T cells on survival.
Hazard ratios and associated 95% CI were assessed with the use
of a Cox proportional-hazards model. A paired t-test was used
to compare KLH proliferation in time. Ulceration was assumed
absent if not reported in the pathology report. p values less
than 0.05 were considered signiﬁcant. SPSS version 20.0 soft-
ware (SPSS Inc., Chicago, IL) and Graphpad Prism 5.03
(GraphPad Software inc, San Diego, CA) were used for statisti-
cal analysis.
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